Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Advanced Dedifferentiated Liposarcoma
NCT04967521Phase 3Active, not recruiting
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dedifferentiated liposarcoma (DDL) comparing Abemaciclib with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Started Nov 2021; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT04967521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967521.